As number of COVID-19 cases in Russia crossed 500,000, the government has rolled out a drug to treat the novel coronavirus even though clinical trials are still underway.
The country's health ministry has approved the use of the anti-viral drug, registered under the name Avifavir, under a special accelerated process.
In a press release, the state financial backer said the drug has been delivered to some hospitals and clinics in the country.
The country's RDIF sovereign wealth fund has a 50 per cent share in a joint venture with the drug's manufacturer ChemRar.
There is currently no vaccine for COVID-19, with human trials of several existing antiviral drugs yet to show efficacy.
So far, the country has 502,436 positive cases and the death toll stands at 6,532.


Reopening of Gaza's Rafah crossing expected Monday
Winter storm death toll in United States reaches 90
Pakistan says 145 militants killed after attacks in Balochistan
Israeli strikes kill 26 in Gaza, health officials say
US government starts likely brief shutdown as House fails to approve deal
Thousands demonstrate in Minnesota and across US to protest ICE
France tightens infant milk rules after recalls
Modi ally proposes social media ban for India's teens as global debate grows
